Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTHXFA1)

DTT Name	C5a anaphylatoxin chemotactic receptor (C5AR1) DTT Info
Gene Name	C5AR1

Molecule-Related Drug & Molecule List

Molecule-Related Drug List

Molecule Type:

DTT

DTP

DME

Drug Status:

Discontinued Drug(s)

Approved Drug(s)

Clinical Trial Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avacopan	DM5LQHB	Anca-associated vasculitis	4A44.A	Approved	[1]
------------------------------------------------------------------------------------

1 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[2]
------------------------------------------------------------------------------------

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NN8209	DM2TDE7	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[3]
NN8210	DM8Z5VH	Rheumatoid arthritis	FA20	Discontinued in Phase 1	[3]
------------------------------------------------------------------------------------

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMX205	DMMXR3L	Central nervous system disease	8A04-8D87	Preclinical	[4]
------------------------------------------------------------------------------------

4 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
C5aR pepducins	DMEK4HZ	Inflammation	1A00-CA43.1	Investigative	[5]
NDT9520492	DMFKX7Z	Discovery agent	N.A.	Investigative	[6]
RPR121154	DM9DXHM	Discovery agent	N.A.	Investigative	[5]
W54011	DMQI7BA	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------

Molecule Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

References

1	Clinical pipeline report, company report or official report of ChemoCentryx.
2	Company report (Arana Therapeutics)
3	Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol. 2013 Apr 15;190(8):3839-47.
4	Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice. Sci Rep. 2018 May 25;8(1):8101.
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 32).
6	Molecular characterization of the gerbil C5a receptor and identification of a transmembrane domain V amino acid that is crucial for small molecule ... J Biol Chem. 2005 Dec 9;280(49):40617-23.
7	Identification of a potent and orally active non-peptide C5a receptor antagonist. J Biol Chem. 2002 Dec 20;277(51):49403-7.